Moxetumomab pasudotox-tdfk in heavily retreated r/r hairy cell leukaemia

Bookmark and Share
Published: 12 Dec 2019
Views: 267
Dr Robert Kreitman - National Cancer Institute, Bethesda, USA

Moxetumomab pasudotox-tdfk is a first-in-class recombinant CD22-directed cytotoxin approved in the US for the treatment of adult patients with relapsed/refractory hairy cell leukaemia (HCL).

Dr Kreitman talks to ecancer at ASH 2019 about his multicentre, open-label, single-arm trial (NCT01829711) which evaluated efficacy, safety, immunogenicity, and pharmacokinetics.

Moxetumomab pasudotox-tdfk treatment was associated with a manageable safety profile.

A high rate of durable responses demonstrated the ability to achieve MRD negativity in heavily pretreated patients with HCL.